José Júlio Costa Sidrim, Daniel Vieira Martins, Maria Gleiciane da Rocha, Géssica Dos Santos Araújo, Rossana de Aguiar Cordeiro, Glaucia Morgana de Melo Guedes, Waldemiro de Aquino Pereira-Neto, Débora de Souza Collares Maia Castelo-Branco, Marcos Fábio Gadelha Rocha
{"title":"香叶醇可抑制副丝状念珠菌菌种群的浮游细胞和生物膜:两性霉素 B、卡泊芬净和氟康唑加香叶醇可提高疗效的亮点。","authors":"José Júlio Costa Sidrim, Daniel Vieira Martins, Maria Gleiciane da Rocha, Géssica Dos Santos Araújo, Rossana de Aguiar Cordeiro, Glaucia Morgana de Melo Guedes, Waldemiro de Aquino Pereira-Neto, Débora de Souza Collares Maia Castelo-Branco, Marcos Fábio Gadelha Rocha","doi":"10.1093/mmy/myae105","DOIUrl":null,"url":null,"abstract":"<p><p>The Candida parapsilosis species complex poses a recognized threat to the nosocomial environment. In the scenario of the global rise of resistant strains to antifungals, geraniol, a terpene isolated from different essential oils, has shown promising antimicrobial activity. We evaluated: (1) the effects of geraniol against the C. parapsilosis species complex, in planktonic and biofilm forms; (2) the strains' susceptibility to clinical antifungals and (3) the geraniol interaction with antifungals. Eighteen isolates were subjected to in vitro susceptibility testing by the broth microdilution protocol, using geraniol, amphotericin B, caspofungin, itraconazole and fluconazole to determine the minimum inhibitory concentration (MIC) and subsequently, we measured the fungicidal activity. Geraniol was tested against biofilms by the measurement of the metabolic activity and biomass. Pharmacological interactions were performed by the checkerboard method. Geraniol's MIC range was between 256 and 512 µg/ml. MIC range for clinical antifungals was ≤ 0.031-4 µg/ml. Geraniol also showed antibiofilm activity with average reductions of metabolic activity (38.33%) and biomass (30.69%), at MIC concentration. Furthermore, geraniol showed synergistic/additive effects with antifungals. Briefly, geraniol inhibits both planktonic cells and biofilms of the C. parapsilosis species complex and besides it improves the efficacy of amphotericin B, caspofungin and fluconazole.</p>","PeriodicalId":18586,"journal":{"name":"Medical mycology","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Geraniol inhibits both planktonic cells and biofilms of the Candida parapsilosis species complex: Highlight for the improved efficacy of amphotericin B, caspofungin and fluconazole plus Geraniol.\",\"authors\":\"José Júlio Costa Sidrim, Daniel Vieira Martins, Maria Gleiciane da Rocha, Géssica Dos Santos Araújo, Rossana de Aguiar Cordeiro, Glaucia Morgana de Melo Guedes, Waldemiro de Aquino Pereira-Neto, Débora de Souza Collares Maia Castelo-Branco, Marcos Fábio Gadelha Rocha\",\"doi\":\"10.1093/mmy/myae105\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The Candida parapsilosis species complex poses a recognized threat to the nosocomial environment. In the scenario of the global rise of resistant strains to antifungals, geraniol, a terpene isolated from different essential oils, has shown promising antimicrobial activity. We evaluated: (1) the effects of geraniol against the C. parapsilosis species complex, in planktonic and biofilm forms; (2) the strains' susceptibility to clinical antifungals and (3) the geraniol interaction with antifungals. Eighteen isolates were subjected to in vitro susceptibility testing by the broth microdilution protocol, using geraniol, amphotericin B, caspofungin, itraconazole and fluconazole to determine the minimum inhibitory concentration (MIC) and subsequently, we measured the fungicidal activity. Geraniol was tested against biofilms by the measurement of the metabolic activity and biomass. Pharmacological interactions were performed by the checkerboard method. Geraniol's MIC range was between 256 and 512 µg/ml. MIC range for clinical antifungals was ≤ 0.031-4 µg/ml. Geraniol also showed antibiofilm activity with average reductions of metabolic activity (38.33%) and biomass (30.69%), at MIC concentration. Furthermore, geraniol showed synergistic/additive effects with antifungals. Briefly, geraniol inhibits both planktonic cells and biofilms of the C. parapsilosis species complex and besides it improves the efficacy of amphotericin B, caspofungin and fluconazole.</p>\",\"PeriodicalId\":18586,\"journal\":{\"name\":\"Medical mycology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2024-11-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical mycology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/mmy/myae105\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical mycology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/mmy/myae105","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
摘要
副丝状念珠菌复合体对医院环境构成了公认的威胁。在全球抗真菌药物耐药菌株增多的情况下,从不同精油中分离出来的萜烯类物质香叶醇显示出了良好的抗菌活性。我们评估了1- 香叶醇对浮游和生物膜形式的副丝状念珠菌复合菌株的作用;2- 菌株对临床抗真菌药物的敏感性;3- 香叶醇与抗真菌药物的相互作用。我们采用肉汤微稀释法对 18 个分离菌株进行了体外药敏试验,使用香叶醇、两性霉素 B、卡泊芬净、伊曲康唑和氟康唑来确定最低抑菌浓度(MIC),然后测定其杀菌活性。香叶醇通过测定代谢活性和生物量,对生物膜进行了测试。药理作用采用棋盘格法进行。香叶醇的 MIC 范围在 256 至 512 µg/ml 之间。临床抗真菌药物的 MIC 范围≤ 0.031-4 µg/ml。香叶醇还具有抗生物膜活性,在 MIC 浓度下,代谢活性(38.33%)和生物量(30.69%)平均降低。此外,香叶醇还显示出与抗真菌药的协同/叠加效应。简而言之,香叶醇对副丝状念珠菌的浮游细胞和生物膜都有抑制作用,此外,它还能提高两性霉素 B、卡泊芬净和氟康唑的疗效。
Geraniol inhibits both planktonic cells and biofilms of the Candida parapsilosis species complex: Highlight for the improved efficacy of amphotericin B, caspofungin and fluconazole plus Geraniol.
The Candida parapsilosis species complex poses a recognized threat to the nosocomial environment. In the scenario of the global rise of resistant strains to antifungals, geraniol, a terpene isolated from different essential oils, has shown promising antimicrobial activity. We evaluated: (1) the effects of geraniol against the C. parapsilosis species complex, in planktonic and biofilm forms; (2) the strains' susceptibility to clinical antifungals and (3) the geraniol interaction with antifungals. Eighteen isolates were subjected to in vitro susceptibility testing by the broth microdilution protocol, using geraniol, amphotericin B, caspofungin, itraconazole and fluconazole to determine the minimum inhibitory concentration (MIC) and subsequently, we measured the fungicidal activity. Geraniol was tested against biofilms by the measurement of the metabolic activity and biomass. Pharmacological interactions were performed by the checkerboard method. Geraniol's MIC range was between 256 and 512 µg/ml. MIC range for clinical antifungals was ≤ 0.031-4 µg/ml. Geraniol also showed antibiofilm activity with average reductions of metabolic activity (38.33%) and biomass (30.69%), at MIC concentration. Furthermore, geraniol showed synergistic/additive effects with antifungals. Briefly, geraniol inhibits both planktonic cells and biofilms of the C. parapsilosis species complex and besides it improves the efficacy of amphotericin B, caspofungin and fluconazole.
期刊介绍:
Medical Mycology is a peer-reviewed international journal that focuses on original and innovative basic and applied studies, as well as learned reviews on all aspects of medical, veterinary and environmental mycology as related to disease. The objective is to present the highest quality scientific reports from throughout the world on divergent topics. These topics include the phylogeny of fungal pathogens, epidemiology and public health mycology themes, new approaches in the diagnosis and treatment of mycoses including clinical trials and guidelines, pharmacology and antifungal susceptibilities, changes in taxonomy, description of new or unusual fungi associated with human or animal disease, immunology of fungal infections, vaccinology for prevention of fungal infections, pathogenesis and virulence, and the molecular biology of pathogenic fungi in vitro and in vivo, including genomics, transcriptomics, metabolomics, and proteomics. Case reports are no longer accepted. In addition, studies of natural products showing inhibitory activity against pathogenic fungi are not accepted without chemical characterization and identification of the compounds responsible for the inhibitory activity.